Focused On-demand Library for Interferon alpha/beta receptor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P17181

UPID:

INAR1_HUMAN

Alternative names:

Cytokine receptor class-II member 1; Cytokine receptor family 2 member 1; Type I interferon receptor 1

Alternative UPACC:

P17181; B2R6L9; B4DNT3; D3DSF0; Q53GW9; Q53H11; Q6PKD7; Q7M4L2; Q8WTZ2

Background:

Interferon alpha/beta receptor 1, also known as Cytokine receptor class-II member 1, plays a pivotal role in the immune response. It forms a heterodimeric receptor with IFNAR2 for type I interferons, activating the JAK-STAT signaling pathway, which is crucial for the transcriptional regulation of interferon-regulated genes.

Therapeutic significance:

The protein's involvement in Immunodeficiency 106, characterized by increased susceptibility to viral infections and severe reactions to certain vaccines, highlights its therapeutic potential. Targeting this receptor could lead to innovative treatments for viral infections and immune disorders.